Alerts
Using germfree animal models to prove the role of the gut microbiota in liver diseases
Dr. Philippe Gérard from INRA, France will talk about "Using germfree animal models to prove the role of the gut microbiota in liver diseases" during 6th World Congress on Targeting Microbiota 2018 Congress which will be held in October 28-30, 2018, at Porto, Portugal.
Summary of talk: The portal vein conducts blood from the gastrointestinal tract to the liver which is thus one of the main organ that can be influenced by microbiome composition and activities. Nonalcoholic and alcoholic fatty liver disease (NAFLD and ALD, respectively) refers to a spectrum of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis, advanced fibrosis, cirrhosis or even hepatocellular carcinoma. Using microbiota transplants from conventional mice or human alcoholic patients to germ-free mice, we demonstrated that the gut microbiota determines development of NAFLD and that the individual susceptibility to ALD may be driven by intestinal bacteria. This suggests that targeting the gut microbiota could be a new prevention or therapeutic approach for liver diseases management.
For more information: www.microbiota-site.com
Can gut phages be used to improve the health of stunted children?
During the 6th World Congress on Targeting Microbiota 2018 which will be held at Porto, Portugal, in October 28-30, 2018, Dr Mohammadali Khan Mirzaei from McGill University, Canada will present his research on "Role of gut phages in child stunting".
Short summary: "Child stunting is a significant health concern in low and middle-income countries. Delayed and reduced growth or stunting results from nutrition deficiencies, genetics, and an altered gut microbiota. Recent studies have shown that gut bacteria of stunted children are different from their normal counterparts, generally with lower Firmicutes/Proteobacteria ratio. While the role of bacteriophages (phages for short) in regulating bacterial populations in the environment is well studied, their role in gut dysbiosis is unknown. In collaboration with the International Centre for Diarrhoeal Disease Research, Bangladesh, we have studied the role of phages in healthy and stunted children from Bangladesh. The main goal of our study is to determine if gut phages can be used to manipulate gut bacterial communities to improve the health of stunted children."
Targeting Microbiota 2018
www.microbota-site.com
Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases
Maria Cecilia Giron from University of Padova, Italy will talk about "Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases" during the 6th World Congress on Targeting Microbiota 2018 Congress.
"In the last decade, emerging evidence has revealed the presence of an intense dialogue between the brain and the gastrointestinal system, the so-called brain-gut axis. Disruption of this complex relationship has been shown to be associated to the pathogenesis of several disorders, ranging from irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), to depression, anxiety, dementia and Parkinson’s disease.
We have demonstrated that gut dysbiosis affects functional and structural integrity of the enteric nervous system. We are currently examining a potential microbiota-gut-brain axis involved in neuroplasticity and neurodegeneration. Deciphering the interactive dialogue that occurs between microorganisms in the gut and the activity of the immune system regulated by Toll-like receptors is crucial for the discovery and the development of compounds such as pharma- and nutraceuticals (including syn-, pre- and probiotics), critical for preserving or restoring homeostasis in the gut as well as in the central nervous system."
Targeting Microbiota 2018
www.microbota-site.com
Link between microbiota & visceral pain: role of bioactive lipids
Dr. Nicolas Cenac from Inserm, France will join the 6th World Congress on Targeting Microbiota 2018 Congress and give presentation about "Link between microbiota & visceral pain: role of bioactive lipids".
"Impairment in the composition and diversity of this microbiota have been observed in pathologies of digestive tract such as irritable bowel syndrome (IBS). In order to study the impact of bacteria on the most deleterious IBS symptoms, visceral pain, we used several approaches in mass spectrometry to analyze bacterial lipids. We highlighted the production by bacteria of lipopeptides able to cross the intestinal barrier to regulate sensory neurons. In addition, we characterized several long chain fatty acid (LCFA) modifying the production of pro-algesic molecules by intestinal epithelial cells. These works allowed us to demonstrate that bacteria from the microbiota, by secreting lipopeptides and LCFAs, could signal directly or via the epithelium to sensory neurons."
For more information: www.microbiota-site.com
Crosstalk between Gut Microbiota, Innate Immune Cells and Endocrine Cells in the Pancreas Regulates Autoimmune Diabetes
Dr. Julien Diana from Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France will present his study entitled "Crosstalk between Gut Microbiota, Innate Immune Cells and Endocrine Cells in the Pancreas Regulates Autoimmune Diabetes" during the Targeting Microbiota 2018 Congress, which will be held in Porto, in October 28-30, 2018.
In his presentation, Dr. Diana will highlight: "The gut microbiota is essential for the normal function of the gut immune system. However how the gut microbiota prevents autoimmunity in distant organs remains poorly defined. Our group recently described that the gut microbiota controls the production of antimicrobial peptides (AMPs) by the pancreatic endocrine cells. Importantly, owing to their immunoregulatory properties, AMPs are critical to maintain the immune tolerance in the pancreas. In the NOD mice, a mouse model of autoimmune diabetes, we demonstrated that dysbiosis leads to a defective production of AMPs in the pancreas and to the development of the disease. Our findings reveal a novel interplay between the gut microbiota, the endocrine cells and the immune system that contributes in preventing autoimmune diabetes.”
For more information: www.microbiota-site.com
MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response
Dr. Antonio Riva from Institute of Hepatology London, Foundation for Liver Research, United Kingdom will join the Porto Microbiota 2018 Congress which will be held in October 28-30, 2018, at Porto, Portugal and will give presentation entitled "MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response".
Summary of presentation: "The liver is an immunologically active filter that clears the portal blood of food antigens, nutrients and chemical/cellular compounds produced or released by the gut microbiota. With increasing severity of liver disease not only is this ability progressively lost, but we also observe changes in the gut flora, increased gut permeability, increased gut bacterial translocation, a progressive immune deterioration, and increasing susceptibility to bacterial infections that represent a major cause of death in patients with advanced liver disease.
MAIT cells are essential players of the antibacterial immunity and their tissue distribution is intimately linked to the gut-liver axis. Indeed, MAIT cells are highly enriched in the liver and recirculate between the liver and the gut via the portal and the peripheral circulation.
We were the first to describe MAIT cell alterations in alcoholic liver disease and to show that these alterations are gut-related, and we believe that MAIT cell defects are crucial in the dysfunctional antibacterial immunity observed in patients with liver disease."
The relationship between the microbiota, immune system and behaviour
Paul Forsythe from McMaster University, Canada will join the Porto Microbiota 2018 Congress which will be held in October 28-30, 2018, at Porto, Portugal and will talk about "Psycho neuro immunology and gut microbes" during the congress.
Paul Forsythe highlighted: "There is increasing evidence that gut microbes can influence brain chemistry and function, and disruption of the microbiota may contribute to neuro-developmental and mood disorders. However, the mechanisms underlying communication between gut microbes and the brain are complex and still poorly understood. This presentation will focus on the relationship between the microbiota, immune system and behaviour, describing recent experiments that highlight gut microbes as key agents in psychoneuroimmunology."
For more information: www.microbiota-site.com
What are the effects of gut bacterial metabolites on cardiovascular risk?
Dr Marcin Ufnal from Medical University of Warsaw, Poland will join the Porto Microbiota 2018 Congress which will be held in October 28-30, 2018, at Porto, Portugal and will talk about "The effect of gut bacterial metabolites on cardiovascular risk" during the congress.
Dr Ufnal will highlight: "Gut bacteria-produced compounds enter the bloodstream and affect the circulatory system. For example, trimethylamine N-oxide (TMAO), a gut bacteria metabolite of L-carnitine and choline, has recently emerged as a new diagnostic marker and mediator of increased cardiovascular risk. However, the mechanism is not clear.Recently we have found that high sodium intake and treatment with ACE-inhibitors affect blood concentration of TMAO in rats. This suggests that plasma level of gut bacterial metabolites may correlate with interventions modifying cardiovascular risk."
For more information: www.microbiota-site.com
Microbiota & Medicine of Tomorrow: Big data, Artificial Intelligence and Revolution
Prof. Marvin Edeas, Institut Cochin, Université Paris Descartes, France, as founder of the International Society of Microbiota (ISM) and member of the scientific steering board, delivered his vision about the next ISM meeting:
"...We wish to connect and bridge all pathologies (cardiovascular, neurodegenerative, metabolic diseases, cancer and ageing) to microbiota (diversity) to find new strategies.
We want to initiate a new way of thinking, and how to integrate Microbiota Medicine, Big data generated by gut microbiota sequencing and Artificial Intelligence.
This ambitious project needs a multi Task Force. We need to open new "doors" to medicine of tomorrow and anticipate in this field.
I wish also to highlight the strategies to modulate the quality of microbiota by phages and the strategic intertalk with mitochondria.
The field of phagotherapy and microbiota will be largely discussed during Porto Microbiota 2018.
The other hot topic will be the exact role of short chain fatty acids and H2S. These key factors will modulate mitochondria activity ..."
The 6th World Congress on Targeting Microbiota will be organized in Porto, Portugal in October 28-30, 2018.
For more information: www.microbiota-site.com
The sunny city of Porto will host the 6th World Congress on Targeting Microbiota in October 28-30, 2018.
The scientific and organizing committee of the International Society of Microbiota informed you that the 6th World Congress on Targeting Microbiota, was relocated at the Hotel Crowne Plaza, Porto, Portugal and will be held on October 28-30, 2018.
You can acces the preliminary agenda by clicking here.
For more information, please don't hesitate to contact us.
Food & Microbiota 2018: What are the three strategic questions?
The first ISM Symposium on Food & Microbiota 2018: Towards a New era in Agro-Food in Industry will be held in June 14, 2018, in Paris, France.
What is the aim of Microbiota & Food 2018?
Microbiota & Food 2018 will target the recent advances in microbiota and interaction with food.
We will highlight the effects of microbiota metabolites after food ingestion and the perspectives of their applications in humans.
How to integrate all regulatory aspects in food strategies?
We will highlight the strategic topic of the regulatory aspects in the industry and how these regulatory guidelines have impact on academic and clinical science.
We will present the different regulatory categories of products (food for special medical purpose, food supplements, infant formula...).
What kind of applications and ideas will be discussed?
In the latest part, we will highlight the practical aspects and potential applications in agro-food industry, infant formula, dairy products and all food formulations aimed to prevent and treat diseases.
We will present the innovations related to microbiota applications in the different agro-food industries (probiotics, robiotics, fermented food, functional ingredients...).
To access the agenda of food & microbiota 2018, please click here.
More information on www.microbiota-site.com
Food & Microbiota 2018: The first symposium will be organized in June 14
The International Society of Microbiota (ISM) organizes the first ISM Symposium on Microbiota & Food, which will be held in Paris in June 14, 2018.
Nowadays, the studies about microbiota are revolutionizing the clinical and health research.
Report of the 5th ISM Berlin Microbiota Congress 2017
For this 5th edition of ISM World Congress on Microbiota, which was held on October 26-27, 2017, the organizing committee had decided to move to a new city: Berlin. According to the President of ISM "Berlin has been a fantastic location and a fascinating city full of history and discoveries….just like the Microbiota!". Indeed, the 5th edition gathered more than 280 attendees coming from universities, clinics, start-up and international industries dealing with all fields related to microbiota.
ISM communication award 2017 for a presentation about Exploring the gut microbiome role in Parkinson’s disease and in primary parkinsonisms
The scientific committee of the 5th World Congress on Targeting Microbiota discerned the ISM oral communication award to Dr. Clarissa Consolandi, from the National Research Council, Italy for her presentation about "Exploring the gut microbiome role in Parkinson’s disease and in primary parkinsonisms".
Testimonial from Dr. Consolandi: "It is a great honor for me to be awarded by the ISM. My work was about the study of the gut microbiome (GM) role in Parkinson’s disease and in primary parkinsonisms. Our results showed a considerable altered GM profile in patients compared to their co-living healthy controls with an evolution of the microbial profile visible during the progression of the disease. So, specific microbial groups could be used in the future as fingerprints of the disease progression. In addition, the preliminary data collected from the twins dataset could also provide key information on the risk factors for the development of the disease, since they share most of the key factors that determine the composition of GM in the early stages of life and this model is devoid of bias due to genetic variability.
Targeting Microbiota Congress represents a great opportunity to exchange ideas with the leading scientists and share the latest developments in the field, providing chance for brainstorming also during breaks and poster sessions."To access the global report of Targeting Microbiota 2017, please follow this link.
For more information: www.microbiota-site.com
The final agenda of the 5th World Congress on Targeting Microbiota is now online
The abstracts book of the 5th World Congress on Targeting Microbiota, which will be held in Berlin, Germany on October 26-27, 2017 is now available.
During both days, more than 50 oral communications and 50 posters will be presented. Around 300 attendees coming from clinics, universities, and industries will gather and network around the poster presentations.
To access the list of attendees, please follow this link.
To access the list of communications, please follow this link.
We remind you that you can still join the attendees and participate to the congress by registering here.
If you cannot take part to the congress, you can order the abstracts book here.
We look forward to meeting you in Berlin next week.
ISM Secretariat
www.microbiota-site.com
The ISM poster presentation was discerned to Dr. de Grandi, University of Milan, Italy
During two days, more than 70 posters were presented during Targeting Microbiota Congress. At the end of the second day, the scientific committee selected Dr. de Grandi's poster and awarded her.
Dr. de Grandi is coming from the Laboratory of Clinical Microbiology, Department of Biomedical Sciences for Health at University of Milan, Italy and the subject of her poster was about "Microbiota and salivary calculi: a new challenge for microbiologists".
Testimonial from Dr de Grandi:
"Targeting Microbiota Congress is a unique opportunity for biomedical researchers (biologists, physicians and bioinformaticians) to meet and share ideas with the leading scientists in the Microbiome research field. Furthermore, participation in the meeting gives an opportunity to improve knowledge about mechanisms by which the microbiota interacts with the host; the meeting is also, an opportunity for each participant to prove himself with both a high-level context and great experts of microbiota field.
It was a great pleasure for me to attend this conference in Berlin: I particularly appreciated the careful selection of lectures to highlight the state-of-the-art in the field and I was enthusiastic about the great number and extremely interesting works that were presented. The conference provided many opportunities for networking, discussions and brainstorming opening up the mind not only to the improvement of current studies, but also to new research ideas. Of particular interest for my activities were the talks about the standardization methods necessary for 16S rDNA library preparation and bioinformatic data analysis, since metagenomics may have several potential applications in clinical microbiology, translating the Microbiome research in an effective tool for a human personalized medicine."
To access the global report of Targeting Microbiota 2017, please click here.
For more information about the congress: www.microbiota-site.com
What are the recent advances in fecal microbiota therapy?
Prof. Peter C. Konturek from Thuringia Clinic Saalfeld, Teaching Hospital of the University of Jena, Germany will present the recent advances on fecal microbiota therapy during Targeting Microbiota World Congress 2017.
What are the metabolic, epigenetic, and transgenerational effects of gut bacterial choline consumption?
Dr. Federico Rey, from University of Wisconsin-Madison, USA will present his study related to "Metabolic, epigenetic, and transgenerational effects of gut bacterial choline consumption" during the 5th Targeting Microbiota World Congress 2017.
Choline is an essential nutrient and methyl donor required for epigenetic regulation. In the study published in July 2017 (available here) assessed the impact of gut microbial choline metabolism on bacterial fitness and host biology by engineering a microbial community that lacks a single choline-utilizing enzyme. Dr Rey's team results indicate that choline-utilizing bacteria compete with the host for this nutrient, significantly impacting plasma and hepatic levels of methyl-donor metabolites and recapitulating biochemical signatures of choline deficiency. Mice harboring high levels of choline-consuming bacteria showed increased susceptibility to metabolic disease in the context of a high-fat diet. Furthermore, bacterially induced reduction of methyl-donor availability influenced global DNA methylation patterns in both adult mice and their offspring and engendered behavioral alterations. These results reveal an underappreciated effect of bacterial choline metabolism on host metabolism, epigenetics, and behavior. This work suggests that interpersonal differences in microbial metabolism should be considered when determining optimal nutrient intake requirements.
For more information about Targeting Microbiota Congress, which will be held in Berlin on October 26-27, 2017: www.microbiota-site.com
The role of microbiota in Graft-versus-Host Disease (GvHD) and complications of allogeneic stem cell transplantation
The gut microbiota seem to play a central role in the outcome of patients undergoing allogeneic stem cell transplantation. During the course of allogeneic stem cell transplantation a loss of intestinal microbiota diversity and a shift toward an enteropathogeneic flora were observed, which were aggravated in individuals with systemic broad-spectrum antibiotic treatment and patients suffering from acute gastrointestinal GvHD. Particularly commensal bacteria seem to be crucial for the maintenanace of immunological homeostasis and intestinal epithelial integrity and therefore contribute to the success of allogeneic stem cell transplantation.
During Targeting Microbiota World Congress 2017, Dr Daniela Weber from Regensburg Universitätsklinikum, Germany will highlight the role of microbiota in Graft-versus-Host Disease (GvHD) and complications of allogeneic stem cell transplantation.
For more information: www.microbiota-site.com
RNA-based stable isotope probing to link structure and function of prebiotics-assimilating intestinal microbiotas
Dr. Markus Egert from Furtwangen University, Germany will give a talk during the 5th Targeting Microbiota World Congress 2017 on "RNA-based stable isotope probing to link structure and function of prebiotics-assimilating intestinal microbiotas"
Despite their great economic and therapeutic importance, still little is known about which microorganisms actually degrade and assimilate prebiotic carbohydrates within a complex intestinal microbiota. However, such knowledge is essential to better understand the mode of action of prebiotics in general. Stemming from environmental microbiology, RNA-based stable isotope probing (RNA-SIP) represents a powerful technique to link the identity of distinct microorganisms to the assimilation of a certain, stable istope-labelled substrate. The presentation will particularity focus on the digestive fate of resistant starch when being consumed by microbiotas of mice and human origin.
Dr Markus Egert received an award during the 2nd Symposium on Skin Microbiota for his scientific contribution. More information about the award here.
For more information about Targeting Microbiota Congress, which will be held in Berlin on October 26-27, 2017: www.microbiota-site.com
What are the recent advances related to the human infant gut microbiota mobilome?
Dr. Knut Rudi from Norwegian University of Life Sciences, Norway will present his study related to "The human infant gut microbiota mobilome " during the 5th Targeting Microbiota World Congress 2017.
According to him: "The microbial ecosystem residing in the human gastrointestinal tract plays an intimate role in the development and well-being of their human host. The gut commensal microbes reside in synergy with the host, undertaking wide range of functions that benefits themselves and their host. These host-associated microbial communities that share different functional genes between distinct bacterial species are increasingly associated with horizontal gene transfer (HGT). Mobile genetic elements (MGEs) such as plasmids, transposons and integrons are main contributors to HGT. The human gut microbiota are reservoirs to multiple AR genes that in turn are associated with wide range of MGEs. These elements additionally harbor novel genes that attributes towards the host microbe properties. However, the distribution and association of MGEs in the developing gut microbiota remains largely unexplored. Current status and future developments in our knowledge about the infant gut microbiota mobilome will be discussed".
For more information about Targeting Microbiota Congress, which will be held in Berlin on October 26-27, 2017: www.microbiota-site.com
